Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

IsoRay, Inc. (ISR) is “One to Watch”

|Includes: IsoRay, Inc. (ISR)

IsoRay, Inc. is utilizing its patented radioisotope technology, experienced chemists and engineers, and management team to create a medical device company focused on providing improved patient outcomes in the treatment of prostate cancer, lung cancer, ocular melanoma cancer, brain cancer, colorectal cancer, gynecological cancer, and other cancers throughout the body. Through its subsidiary, IsoRay Medical, the Company is the sole producer of FDA-cleared Cesium-131 brachytherapy seeds.

IsoRay began production and sales of Cesium-131 brachytherapy seeds in October 2004. The Company is leveraging its technology to capture a leadership position in an expanded brachytherapy market. The more clinically beneficial characteristics of the Cesium-131 isotope are expected to decrease radiation exposure to the patient and reduce the severity and duration of side effects, while treating cancer cells as effectively, if not more so, than Iodine-125 or Palladium-103.

In recent news, IsoRay announced that doctors have performed the world’s first treatment of metastasized brain cancer using its Cesium-131 brachytherapy seeds. The seeds were implanted directly into a woman’s brain to treat a cancer that had originated in the breast. Treatment of metastasized cancers, cancers that originate in other organs, is the latest application of IsoRay’s brachytherapy treatment that represents one of the most important advancements in internal radiation therapy in the last 20 years.

IsoRay CEO Dwight Babcock emphasized that this treatment is only the beginning, predicting that the adoption of Cesium-131 for the treatment of primary and metastasized cancers will continue growing and gain momentum as the medical community becomes aware of the significant advantages it offers in treating cancer sites throughout the body. The pioneering treatment increases life expectancy and limits the potential of recurrence, while improving quality of life and allowing patients to return to normal activities more quickly.

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html